缺乏同源病毒时口蹄疫抗原性疫苗匹配的新方法
本研究评估一种无需同源疫苗病毒信息的口蹄疫疫苗匹配新技术,对1991-2015年南部非洲分离的41株SAT1和SAT2型口蹄疫病毒进行病毒中和试验,比较接种疫苗牛血清与恢复期牛血清的r1值。新方法与验证方法在SAT1(Spearman's rho=0.84, P<0.01)和SAT2(rho=0.90, P<0.01)均强相关,基于r1值0.3 cut-off的PABAK一致性分别为0.67和0.84。
要点
- 新r1值法无需同源疫苗病毒即可评估口蹄疫疫苗匹配度。
- SAT1和SAT2病毒新方法与验证方法r1值强相关(rho=0.84和0.90)。
- 以r1值0.3为cut-off,两方法一致性中等至良好(PABAK 0.67和0.84)。
核心结论
- 新r1值法是一种可行的替代疫苗匹配方法,可惠及南部非洲口蹄疫控制。
研究设计与样本
- 研究评估无需同源疫苗病毒信息的新疫苗匹配技术,作为概念验证。
- 选取1991-2015年南部非洲牛和野生动物来源的41株口蹄疫野毒(20株SAT1和21株SAT2)。
- 对每血清型两组混合血清(接种疫苗牛血清4-16周和恢复期牛血清3周)进行病毒中和试验。
主要发现
- 新r1值与验证方法r1值在SAT1病毒强正相关(Spearman's rho=0.84, P<0.01)。
- SAT2病毒两方法r1值非常强相关(Spearman's rho=0.90, P<0.01)。
- 基于r1值cut-off 0.3,两方法一致性SAT1的PABAK为0.67,SAT2为0.84。
关键数值与推荐
- 新r1值计算为接种疫苗血清滴度与恢复期牛血清滴度的比值。
- 验证r1值基于真实同源疫苗病毒假设计算。
- r1值cut-off 0.3被假定代表良好疫苗匹配。
临床怎么用
- 在缺乏同源病毒时可用新r1值法评估疫苗对流行野毒的交叉保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Foot-and-mouth-disease (FMD) is a highly contagious transboundary animal disease that has negative consequences on regional and international trade. Vaccination is an important approach for FMD control and an essential consideration is the degree of cross-protection conferred by the vaccine against currently circulating field viruses. The objective of this study was to evaluate a new vaccine matching technique that does not require knowledge concerning the homologous vaccine virus. As a proof of concept, the vaccine-match was assessed for 41 FMD field viruses isolated from southern Africa over a 25-year period. A diverse group of 20 SAT1 and 21 SAT2 FMDV isolates collected from cattle and wildlife during 1991-2015 were selected for this study. Virus neutralization tests were performed against two sets of pooled sera for each serotype: vaccinated cattle sera (4-16 weeks post-vaccination) and convalescent cattle sera (3 weeks post-experimental challenge). Novel r1-values were calculated as the ratio of the titre of the vaccinated sera to the titre for convalescent cattle sera. A validation r1-value was calculated based on an assumption concerning the true homologous vaccine virus. There was a strong positive correlation between r1-values for the novel and the validation methods for SAT1 viruses (Spearman's rho = 0.84, P < 0.01) and a very strong correlation for SAT2 viruses (Spearman's rho = 0.90, P < 0.01). In addition, there was moderate to good agreement between the novel and validation methods for both serotypes based on a r1-value cut-off of 0.3, which is presumed to represent a good vaccine-match. The agreement between methods using prevalence-adjusted and bias-adjusted kappa (PABAK) was 0.67 and 0.84 for SAT1 and SAT2 viruses, respectively. The new r1-value method provides a feasible, alternative vaccine matching approach that could benefit FMD control in southern Africa.
引用
- Sirdar MM, Fosgate GT, Blignaut B, et al. A novel method for performing antigenic vaccine matching for foot-and-mouth disease in absence of the homologous virus. Vaccine. 2019. PMID: 31296377. doi:10.1016/j.vaccine.2019.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。